Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2015

Published: Oct, 2015 | Pages: 128 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2015', provides an overview of the Post-Traumatic Stress Disorder (PTSD)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents
 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Post-Traumatic Stress Disorder (PTSD) Overview 10
Therapeutics Development 11
Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Overview 11
Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis 12
Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Development by Companies 13
Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Investigation by Universities/Institutes 15
Post-Traumatic Stress Disorder (PTSD) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Post-Traumatic Stress Disorder (PTSD) - Products under Development by Companies 20
Post-Traumatic Stress Disorder (PTSD) - Products under Investigation by Universities/Institutes 22
Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development 23
Addex Therapeutics Ltd 23
Azevan Pharmaceuticals, Inc. 24
Catalyst Pharmaceutical Partners, Inc. 25
Eli Lilly and Company 26
HolsboerMaschmeyer NeuroChemie GmbH 27
Humanetics Corporation 28
Intra-Cellular Therapies, Inc. 29
Marinus Pharmaceuticals, Inc. 30
Neuralstem, Inc. 31
Neurocrine Biosciences, Inc. 32
NeuroNascent, Inc. 33
Omeros Corporation 34
Otsuka Holdings Co., Ltd. 35
Pfizer Inc. 36
Polleo Pharma Limited 37
Synchroneuron Inc. 38
Tonix Pharmaceuticals Holding Corp. 39
Vanda Pharmaceuticals Inc. 40
Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
acamprosate calcium SR - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ADX-71743 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AM-3506 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
brexpiprazole - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CPP-115 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Drug for Post-Traumatic Stress Disorders - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Drugs to Inhibit FAAH for CNS Disorders - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Drugs to Modulate NPSR for Anxiety Disorder - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ganaxolone - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
HL-9001 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
IC-87201 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
iloperidone - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ITI-007 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
NNI-351 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
NSI-189 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
PF-04457845 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Rycal - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
S-107 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecule to Target GPR151 for CNS Diseases - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecules for Post-Traumatic Stress Disorder - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecules to Antagonize mGluR7 for Post-Traumatic Stress Disorders and Acute Stress Disorder - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
SRX-246 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
TNX-102 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Vaccine for Post-Traumatic Stress Disorder and Depression - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
verucerfont - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
vigabatrin - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
ZL-006 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Post-Traumatic Stress Disorder (PTSD) - Recent Pipeline Updates 95
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects 120
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products 121
Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones 122
Featured News & Press Releases 122
Aug 18, 2015: Tonix Pharmaceuticals Presents on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2015 Military Health System Research Symposium 122
May 26, 2015: Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR 122
May 15, 2015: Tonix Pharmaceuticals Presents Data at the Annual Meeting of the Society for Biological Psychiatry 122
Jan 15, 2015: Tonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder 123
Jun 10, 2014: Tonix Pharmaceuticals Receives IND Clearance From U.S. Food and Drug Administration for TNX-102 SL in Post-Traumatic Stress Disorder 123
Oct 11, 2013: Tonix Pharmaceuticals to Participate in the Women's Healthcare Innovation and Leadership Showcase on October 15, 2013 124
Aug 19, 2013: Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome 124
Oct 24, 2012: Tonix Pharma Completes Pre-IND Meeting With FDA For Potential New Treatment For Post-Traumatic Stress Disorder 125
Oct 15, 2012: Indiana University Scientists Identify New Compound That Could Prevent Post-Traumatic Stress Disorder 125
Oct 15, 2012: Indiana University Scientists Discover New Drug For Preventing Post-Traumatic Stress Disorder 126
Appendix 127
Methodology 127
Coverage 127
Secondary Research 127
Primary Research 127
Expert Panel Validation 127
Contact Us 127
Disclaimer 128

List of Tables

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2015 11
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Development, H2 2015 18
Comparative Analysis by Unknown Stage Development, H2 2015 19
Products under Development by Companies, H2 2015 20
Products under Development by Companies, H2 2015 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2015 22
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H2 2015 23
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals, Inc., H2 2015 24
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2015 25
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Company, H2 2015 26
Post-Traumatic Stress Disorder (PTSD) - Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H2 2015 27
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Humanetics Corporation, H2 2015 28
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Intra-Cellular Therapies, Inc., H2 2015 29
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Marinus Pharmaceuticals, Inc., H2 2015 30
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neuralstem, Inc., H2 2015 31
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neurocrine Biosciences, Inc., H2 2015 32
Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent, Inc., H2 2015 33
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corporation, H2 2015 34
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 35
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Pfizer Inc., H2 2015 36
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Polleo Pharma Limited, H2 2015 37
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Synchroneuron Inc., H2 2015 38
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2015 39
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Vanda Pharmaceuticals Inc., H2 2015 40
Assessment by Monotherapy Products, H2 2015 41
Number of Products by Stage and Target, H2 2015 43
Number of Products by Stage and Mechanism of Action, H2 2015 45
Number of Products by Stage and Route of Administration, H2 2015 47
Number of Products by Stage and Molecule Type, H2 2015 49
Post-Traumatic Stress Disorder (PTSD) Therapeutics - Recent Pipeline Updates, H2 2015 95
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H2 2015 120
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H2 2015 121